GlaxoSmithKline plc (ADR) (NYSE:GSK)

CAPS Rating: 4 out of 5

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.

Results 1 - 20 of 216 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar foolishlymeek (63.33) Submitted: 8/14/2014 11:06:30 PM : Outperform Start Price: $47.25 GSK Score: +0.17

Buy at the bottom!

Recs

0
Member Avatar EdSenior (69.56) Submitted: 7/25/2014 10:49:01 AM : Outperform Start Price: $47.98 GSK Score: -0.59

Good Pipeline of drugs. Vast reach around the world for its products especially with the introduction to them in emerging markets. Slight concern about bad news and great time to pick up some shares.

Recs

0
Member Avatar abrodrip (< 20) Submitted: 3/27/2014 5:54:48 AM : Outperform Start Price: $52.46 GSK Score: -16.44

Whilst the failure of another cancer vaccine is undoubtedly a setback this is entirely to be expected - this proves they are investing and working on new drugs which has to be a good thing for any company. Unless GSK and other Pharmaceutical companies invest in this type of research no progress or growth will be made. GSK WILL eventually succeed in developing new drugs to treat an ageing population (not just cancer) and there WILL be massive demand for drugs.

Recs

0
Member Avatar TMFHelical (98.67) Submitted: 3/14/2014 10:00:12 AM : Outperform Start Price: $53.08 GSK Score: -17.23

Led big pharma in most drugs approved in 2013 with 5 of the ~27. Second to JNJ in approvals over the past 5 years. Solid footing.

Recs

0
Member Avatar afewgoodstocks11 (25.76) Submitted: 2/21/2014 1:46:58 PM : Outperform Start Price: $39.80 GSK Score: -20.94

Div. (Yield) $3.00 (4.4%)
Current Yield . . . . . . .7.35%

Recs

0
Member Avatar Chipperfield (64.82) Submitted: 1/23/2014 1:00:55 PM : Outperform Start Price: $52.53 GSK Score: -17.96

Drugs are promising and pay dividends. Will slightly outperform.

Recs

0
Member Avatar cmrk3 (45.02) Submitted: 8/13/2013 10:16:03 AM : Outperform Start Price: $49.13 GSK Score: -20.66

GSK JV wins FDA approval for HIV drug Tivicay which is supposed to be more effective than Gilead's Atripia, the world's top-selling treatment in the field. There is also Isentress put out by Merk.

Recs

0
Member Avatar Coralreefer1 (28.04) Submitted: 6/29/2013 1:43:27 AM : Outperform Start Price: $47.58 GSK Score: -22.81

Biotech stocks are here to stay as one of the best areas to invest in right now.

Recs

0
Member Avatar wilkeh (47.53) Submitted: 6/6/2013 10:18:02 AM : Outperform Start Price: $48.03 GSK Score: -23.61

diversified healthcare company with good product pipeline

Recs

1
Member Avatar Teacherman333 (48.80) Submitted: 5/26/2013 1:30:25 PM : Outperform Start Price: $48.56 GSK Score: -23.38

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 51.18%
Trailing PE 19.36
PB 11.87
Div yield 4.20%

Recs

0
Member Avatar Xbeam (60.37) Submitted: 4/9/2013 3:59:35 PM : Outperform Start Price: $44.04 GSK Score: -18.22

Any kind of breaktrhough in cancer research or possible cure in HIV will make GSK success.

Recs

0
Member Avatar robotclo (65.51) Submitted: 3/19/2013 2:12:33 AM : Outperform Start Price: $42.39 GSK Score: -15.16

Good year for health care

Recs

1
Member Avatar FJW1000000 (70.73) Submitted: 2/24/2013 11:04:22 PM : Outperform Start Price: $41.42 GSK Score: -14.73

Good company with a good pipeline of drugs. Strong management team. Strong dividend payment. Good long term bet

Recs

1
Member Avatar PsychoDr (92.87) Submitted: 1/15/2013 12:05:15 PM : Outperform Start Price: $40.24 GSK Score: -16.64

Health care industry, 5.28% dividend, low dividend payout percent, history of growing dividend, pharmaceutical with a reasonable pipeline. Depressed earnings due to European crisis and a couple drugs coming off patent protection. Prognosticators are expecting flat earnings for the next two years. With a dividend reinvest position, flat earnings are fine by me. Can yo say cash cow? Share acquisition time people.

Recs

0
Member Avatar Fish08 (64.25) Submitted: 11/13/2012 2:31:07 PM : Outperform Start Price: $38.89 GSK Score: -20.41

Young avg patent life, 12 PE, 4.8% div yield.

Recs

0
Member Avatar flemmingha (54.06) Submitted: 3/24/2012 6:46:06 AM : Outperform Start Price: $40.00 GSK Score: -21.77

over 20 period moving average on a monthly chart

Recs

0
Member Avatar NajdorfSicilian (99.87) Submitted: 11/29/2011 2:34:51 PM : Outperform Start Price: $37.14 GSK Score: -36.77

simply too cheap

Recs

4
Member Avatar BinyaminK (28.98) Submitted: 11/9/2011 1:47:16 PM : Outperform Start Price: $37.75 GSK Score: -33.56

This is a "Giant Tortoise Stock." Like a giant tortoise, It may be big and slow, but it has a hard shell (economic moat), can swim far (enter into new and emerging markets and industries), and live long.

Recs

0
Member Avatar WilliamCrook2003 (71.39) Submitted: 10/21/2011 12:38:54 PM : Outperform Start Price: $38.37 GSK Score: -36.63

Potential to make somebody some money.

Recs

1
Member Avatar MFBriguy (99.88) Submitted: 9/8/2011 12:20:56 PM : Outperform Start Price: $36.09 GSK Score: -33.19

GG Best Buy Now

Featured Broker Partners


Advertisement